EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSNFUG00015016195
Gene Symbol: NTRK3
1 Cross references
202 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSNFUG00015003926
Gene Symbol: NTRK2B
1 Cross references
207 Possible Orthologues:

Nicastrin

Ensembl ID : ENSNFUG00015021428
Gene Symbol: NCSTN
1 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSNFUG00015004116
Gene Symbol: NAMPT
1 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSNFUG00015025179
Gene Symbol: NISCH
3 Cross references
209 Possible Orthologues:

Nociceptin Receptor-Like

Ensembl ID : ENSNFUG00015014067
Gene Symbol: LOC107390557
3 Cross references
168 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSNFUG00015018057
Gene Symbol: NOTCH1B
1 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSNFUG00015000976
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSNFUG00015023300
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSNFUG00015023168
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSNFUG00015007447
Gene Symbol: NR1H3
1 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSNFUG00015024817
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).